0000000000724473

AUTHOR

Tobias Arkenau

showing 2 related works from this author

P-26 RATIONALE 305: Tislelizumab plus chemotherapy versus placebo plus chemotherapy as first-line therapy in patients with gastric or gastroesophagea…

2020

Chemotherapymedicine.medical_specialtybusiness.industrymedicine.medical_treatmentHematologyGastroesophageal Junction AdenocarcinomaPlaceboGastroenterologyFirst line therapyOncologyInternal medicinemedicineIn patientbusinessAnnals of Oncology
researchProduct

530MO Clinical benefit in biomarker-positive patients (pts) with locally advanced or metastatic solid tumours treated with the PARP1/2 inhibitor pami…

2020

Oncologymedicine.medical_specialtyTemozolomidebusiness.industryLow doseLocally advancedHematologyPARP1OncologyInternal medicinemedicineBiomarker (medicine)businessmedicine.drugAnnals of Oncology
researchProduct